Investor Presentation
Filed with ASX · · 24 pages · English
MELBOURNE, 6 September 2021: Anatara Lifesciences (ASX: ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals, is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today to investors. A copy of the presentation is attached. For more information please contact: About Anatara Lifesci
Anatara Lifesciences Ltd on 6ix
In the deck
Earlier from Anatara Lifesciences
- Appendix 4E & Financial Report 30 June 2021
- Anatara Lifesciences Limited (ASX: ANR) Launches IBS-D Clinical Trial Recruitment Website
- Successful Piglet Study
- Monthly Activities/Appendix 4C Cash Flow Report
- Anatara Lifesciences Limited (ASX: ANR) Monthly Activities Report
Later from Anatara Lifesciences
- Anatara Lifesciences Limited (ASX: ANR) Annual Report to Shareholders
- Appendix 4C & Q1 FY22 Activities Report
- AGM CEO Presentation
- Chairmans Address to Shareholders
- Application for quotation of securities - ANR
Follow Anatara Lifesciences into a list and get an email when it puts out news.
Follow Anatara Lifesciences